Biomimetic Prussian blue nanozymes with enhanced bone marrow-targeting for treatment of radiation-induced hematopoietic injury. (February 2023)

• Record Type: Journal Article
• Authors: Zhang, Bowen; Chen, Gan; Wu, Xumin; Li, Yunxing; Xiao, Yao; Li, Jisheng; He, Lijuan; Li, Yunqiao; Wang, Sihan; Zhao, Jiahui; Liu, Chuanli; Zhou, Hong; Li, Yanhua; Pei, Xuetao
• Is Part Of: Biomaterials. Volume 293(2023)
• Publication Date: 2023-02
• Subjects: Prussian blue nanozymes -- Mesenchymal stem cell membrane -- Reactive oxygen species -- Radiation-induced hematopoietic injury -- Targeting therapy; Biomedical materials -- Periodicals; Biocompatible Materials -- Periodicals; Biomatériaux -- Périodiques; 610.28
• DOI: 10.1016/j.biomaterials.2022.121980
• Languages: English
• ISSNs: 0142-9612

Abstract

Abstract: There is an urgent medical need to develop effective therapies that can ameliorate damage to the radiation-exposed hematopoietic system. Nanozymes with robust antioxidant properties have a therapeutic potential for mitigating radiation-induced hematopoietic injury. However, enhancing nanozyme recruitment to injured tissues in vivo while maintaining their catalytic activity remains a great challenge . Herein, we present the design and preparation of a biomimetic nanoparticle, a mesenchymal stem cell membrane camouflaged Prussian blue nanozyme (PB@MSCM), which exhibits biocompatible surface properties and demonstrates enhanced injury site-targeting towards the irradiated murine bone marrow niche. Notably, the constructed PB@MSCM possessed redox enzyme-mimic catalytic activity and could scavenge overproduced reactive oxygen species in the irradiated bone marrow cells, both in vitro and ex vivo . More importantly, the administration of PB@MSCM significantly mitigated hematopoietic cell apoptosis and accelerated the regeneration of hematopoietic stem and progenitor cells. Our findings provide a new targeted strategy to improve nanozyme therapy in vivo and mitigate radiation-induced hematopoietic injury.